TORECAN Drug Patent Profile
✉ Email this page to a colleague
When do Torecan patents expire, and what generic alternatives are available?
Torecan is a drug marketed by Novartis and is included in three NDAs.
The generic ingredient in TORECAN is thiethylperazine maleate. There is one drug master file entry for this compound. Additional details are available on the thiethylperazine maleate profile page.
Summary for TORECAN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 70 |
Clinical Trials: | 1 |
Patent Applications: | 3,411 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TORECAN at DailyMed |
Recent Clinical Trials for TORECAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Rijeka | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for TORECAN
US Patents and Regulatory Information for TORECAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | TORECAN | thiethylperazine malate | INJECTABLE;INJECTION | 012754-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis | TORECAN | thiethylperazine maleate | SUPPOSITORY;RECTAL | 013247-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis | TORECAN | thiethylperazine maleate | TABLET;ORAL | 012753-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |